JP2015526696A5 - - Google Patents

Download PDF

Info

Publication number
JP2015526696A5
JP2015526696A5 JP2015513220A JP2015513220A JP2015526696A5 JP 2015526696 A5 JP2015526696 A5 JP 2015526696A5 JP 2015513220 A JP2015513220 A JP 2015513220A JP 2015513220 A JP2015513220 A JP 2015513220A JP 2015526696 A5 JP2015526696 A5 JP 2015526696A5
Authority
JP
Japan
Prior art keywords
cer
galcer
glc
sphingosine
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015513220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526696A (ja
Filing date
Publication date
Priority claimed from EP12169517.5A external-priority patent/EP2667197B1/en
Application filed filed Critical
Publication of JP2015526696A publication Critical patent/JP2015526696A/ja
Publication of JP2015526696A5 publication Critical patent/JP2015526696A5/ja
Pending legal-status Critical Current

Links

JP2015513220A 2012-05-25 2013-05-24 プロタンパク質転換酵素スブチリシン/ケキシン9型(pcsk9)阻害に対する高感度の有効性および特異性バイオマーカー Pending JP2015526696A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261651569P 2012-05-25 2012-05-25
EP12169517.5 2012-05-25
EP12169517.5A EP2667197B1 (en) 2012-05-25 2012-05-25 Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
US61/651,569 2012-05-25
PCT/EP2013/060816 WO2013175016A1 (en) 2012-05-25 2013-05-24 Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibition

Publications (2)

Publication Number Publication Date
JP2015526696A JP2015526696A (ja) 2015-09-10
JP2015526696A5 true JP2015526696A5 (https=) 2016-11-10

Family

ID=46146755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015513220A Pending JP2015526696A (ja) 2012-05-25 2013-05-24 プロタンパク質転換酵素スブチリシン/ケキシン9型(pcsk9)阻害に対する高感度の有効性および特異性バイオマーカー

Country Status (7)

Country Link
US (1) US20160146842A2 (https=)
EP (1) EP2667197B1 (https=)
JP (1) JP2015526696A (https=)
CN (1) CN104508488A (https=)
CA (1) CA2875419A1 (https=)
ES (1) ES2552371T3 (https=)
WO (1) WO2013175016A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
CA2903946A1 (en) * 2013-03-08 2014-09-12 Zora Biosciences Oy Non-high density lipoprotein derived cvd markers
WO2017097852A2 (en) * 2015-12-07 2017-06-15 Zora Biosciences Oy Use of ceramides and lpls in diagnosing cvd
KR20190049866A (ko) * 2016-09-20 2019-05-09 우시 바이올로직스 아일랜드 리미티드 신규한 항-pcsk9 항체
CN108037275A (zh) * 2017-12-14 2018-05-15 北京豪思生物科技有限公司 一种用于评估冠状动脉疾病的试剂盒
WO2019119049A1 (en) * 2017-12-20 2019-06-27 Baker Heart and Diabetes Institute Method of predicting drug therapeutic responder status and methods of treatment
CN109504737A (zh) * 2018-11-23 2019-03-22 黄河科技学院 一种体外筛选pcsk9抑制剂的方法
WO2022089486A1 (zh) * 2020-10-28 2022-05-05 江苏柯菲平医药股份有限公司 抑制PCSK9基因表达的siRNA及其修饰物与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127192A2 (en) * 2006-04-24 2007-11-08 Duke University Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
CA2658183A1 (en) * 2006-07-17 2008-01-24 Sirna Therapeutics Inc. Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina)
WO2008057459A2 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
EA200901376A1 (ru) * 2007-04-13 2010-12-30 Новартис Аг Молекулы и способы модуляции пропротеинконвертазы субтилизинового/кексинового типа 9(pcsk9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
NZ584902A (en) 2007-10-26 2012-03-30 Schering Corp Anti-pcsk9 and methods for treating lipid and cholesterol disorders
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
US20120238028A1 (en) * 2009-12-01 2012-09-20 Metanomics Health Gmbh Means and Methods for Diagnosing Multiple Sclerosis
EP2529235B1 (en) * 2010-01-29 2019-03-06 Metanomics GmbH Means and methods for diagnosing heart failure in a subject
NO2385374T3 (https=) * 2010-05-05 2014-06-07
CN108445241B (zh) * 2010-06-20 2021-11-02 佐拉生物科学公司 用于鉴定高风险冠状动脉疾病患者的脂质组学标志
EP2592422A1 (en) * 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
EP2592423A1 (en) * 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment

Similar Documents

Publication Publication Date Title
JP2015526696A5 (https=)
Menghini et al. MiR-216a: a link between endothelial dysfunction and autophagy
De Miguel et al. Exercise plasma boosts memory and dampens brain inflammation via clusterin
JP6388284B2 (ja) スタチン治療を受けている冠動脈疾患患者の心血管転帰を予測するためのリピドミックバイオマーカー
Xuan et al. Development of a high coverage pseudotargeted lipidomics method based on ultra-high performance liquid chromatography–mass spectrometry
Lee et al. Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance
CN103154742B (zh) 用于鉴定高风险冠状动脉疾病患者的脂质组学标志
Atalar et al. Assessment of serum galectin-3, methylated arginine and Hs-CRP levels in type 2 diabetes and prediabetes
CN104769434B (zh) 用于2型糖尿病的生物标志物
Itokazu et al. Reduced GM1 ganglioside in CFTR-deficient human airway cells results in decreased β1-integrin signaling and delayed wound repair
Zhang et al. KLF4-PFKFB3-driven glycolysis is essential for phenotypic switching of vascular smooth muscle cells
Marshall et al. Proteomic mapping of proteins released during necrosis and apoptosis from cultured neonatal cardiac myocytes
JP2014532886A5 (https=)
CN103502820B (zh) 用于他汀引发的肌肉毒性的灵敏检测的生物标志物
Zhang et al. Exosomal circEZH2_005, an intestinal injury biomarker, alleviates intestinal ischemia/reperfusion injury by mediating Gprc5a signaling
Abu-Farha et al. Reduced miR-181d level in obesity and its role in lipid metabolism via regulation of ANGPTL3
Patterson et al. Detection of the receptor for advanced glycation endproducts in neuronally-derived exosomes in plasma
Yang et al. Metabolomic profile reveals that ceramide metabolic disturbance plays an important role in thoracic aortic dissection
Walss-Bass et al. X-aptamer technology identifies C4A and ApoB in blood as potential markers for schizophrenia
Anzalone et al. IL-17A-associated IKK-α signaling induced TSLP production in epithelial cells of COPD patients
Takahashi et al. Differential proteome analysis of serum proteins associated with the development of type 2 diabetes mellitus in the KK-Ay mouse model using the iTRAQ technique
JP2017535756A5 (https=)
EP2667197B1 (en) Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
Boi et al. Modified lipid metabolism and cytosolic phospholipase A2 activation in mesangial cells under pro-inflammatory conditions
Doppler et al. Noncanonical atherosclerosis as the driving force in tricuspid aortic valve associated aneurysms-A trace collection